Is the sky the limit? Valeant raises Allergan bid again
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals increased the cash component of its bid for Botox and Restasis maker Allergan by nearly 50% more than its original offer to $72 per share on 30 May, bringing the deal's total potential value to almost $54bn.